Announcement

Collapse
No announcement yet.

BMJ. Complications: tracking down the data on oseltamivir

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • BMJ. Complications: tracking down the data on oseltamivir

    Complications: tracking down the data on oseltamivir -- Cohen 339: b5387 (BMJ, extract, edited)
    Published 8 December 2009, doi:10.1136/bmj.b5387
    Cite this as: BMJ 2009;339:b5387

    Feature

    Complications: tracking down the data on oseltamivir

    Deborah Cohen, BMJ
    dcohen@bmj.com

    Editorial, doi:10.1136/bmj.b5351
    Research, doi:10.1136/bmj.b5106
    Analysis, doi:10.1136/bmj.b5164
    Analysis, doi:10.1136/bmj.b5248
    Letter, doi:10.1136/bmj.b5364


    A Cochrane group?s attempt to reproduce an analysis underpinning the use of oseltamivir in pandemic influenza hit a brick wall. Deborah Cohen retraces its steps

    The first 150 words of the full text of this article appear below.


    It started this July with an inquiry from a Japanese paediatrician, Keiji Hayashi, to the Cochrane Collaboration about its 2008 review of the treatment of influenza with oseltamivir.

    "You described that oseltamivir 150 mg daily prevented lower respiratory tract complications," commented Dr Hayashi. "However, we have found that this conclusion is based on the other review by Kaiser and colleagues1 and not on your own data analysis."

    Hayashi suspected that Kaiser?s conclusion about complications was mainly determined by data from eight unpublished randomised controlled trials (box 1).
    (...)
    -
    <cite cite="http://www.bmj.com/cgi/content/extract/339/dec08_3/b5387">Complications: tracking down the data on oseltamivir -- Cohen 339: b5387 -- BMJ</cite>
Working...
X